ð åèç
å¿
è â 4 Categories of CVD
- Atherosclerotic (CAD, stroke, PAD)
- Heart Failure (HFrEF, HFpEF, HFmrEF)
- Arrhythmias (bradycardia, SVT, VT/VF)
- Structural / Valvular / Cardiomyopathies / Congenital
- Vascular (aortic, peripheral, venous, pulmonary HTN)
å¿
è â 4 Cardinal Symptoms
- Chest pain (angina, MI, PE, dissection, pericarditis, GERD, MSK)
- Dyspnea (HF, ischemia, valvular, PE, pulmonary)
- Palpitations (arrhythmia, ectopy, hyperthyroid, anxiety)
- Syncope (arrhythmia, structural, vasovagal, orthostatic, neurologic)
å¿
è â Biomarkers
- hs-cTn: MI diagnosis; 0/1-hr algorithms
- BNP / NT-proBNP: HF diagnosis + prognosis
- D-dimer: PE / DVT / dissection exclusion (low pretest)
- LDL + Non-HDL + ApoB + Lp(a): lipid risk
å¿
è â Risk Stratification
- ASCVD risk calculator (USA, 10-yr ASCVD)
- PREVENT (AHA 2023+) â newer, includes CKD + metabolic
- SCORE2 (Europe)
- Risk enhancers: family hx, ethnicity, CKD, inflammatory, premature menopause, pregnancy complications, high Lp(a), high CAC
å¿
è â Treatment Targets
- LDL:
- Primary prevention high-risk: < 100 mg/dL (high-intensity statin)
- Secondary / very high risk: < 70 mg/dL (some < 55)
- BP: most adults < 130/80
- HbA1c: individualized; 6.5-7% typical
- Lifestyle: Mediterranean / DASH + exercise + tobacco cessation + weight
å¿
è â Atypical Presentations
- Women + diabetics + elderly: often atypical chest pain (dyspnea, fatigue, nausea)
- Lower threshold for workup
- Silent ischemia common
å¿
è â 2024 CKM Syndrome
- AHA 2023+ framework: Cardiac-Kidney-Metabolic
- Stages 0-4
- Integrated therapy: SGLT2i + GLP-1 RA + finerenone + statin
å¿
è â Syncope Red Flags
- During exertion
- Family hx of sudden death
- Structural heart disease
- Abnormal ECG
- Without prodrome
- Older age + comorbidities